Cargando…

The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on

BACKGROUND: Since 2005 an interdisciplinary German apheresis working group has been established by members of both German Societies of Nephrology and of Lipidologists and completed the data set for the registry according to the current guidelines and the German indication guideline for apheresis in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schettler, V. J. J., Neumann, C. L., Peter, C., Zimmermann, T., Julius, U., Roeseler, E., Heigl, F., Grützmacher, P., Blume, H., Vogt, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352787/ https://www.ncbi.nlm.nih.gov/pubmed/28233268 http://dx.doi.org/10.1007/s11789-017-0089-9

Ejemplares similares

Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels
por: Schettler, Volker J. J., et al.
Publicado: (2015)

Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis
por: Heigl, Franz, et al.
Publicado: (2017)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients
por: Julius, Ulrich
Publicado: (2018)

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection
por: Julius, Ulrich
Publicado: (2016)

Lipid apheresis techniques: current status in Germany
por: Grützmacher, Peter, et al.
Publicado: (2012)

Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias
por: Grützmacher, P., et al.
Publicado: (2015)

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
por: Moriarty, Patrick M., et al.
Publicado: (2016)

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease
por: Heigl, Franz, et al.
Publicado: (2015)

A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV) Registry
por: Schumann, Christian, et al.
Publicado: (2022)

Current view: indications for extracorporeal lipid apheresis treatment
por: Schettler, Volker, et al.
Publicado: (2012)

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis center
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis
por: Weylandt, Karsten-H., et al.
Publicado: (2019)

Lipoprotein apheresis efficacy and challenges: single center experience
por: Özdemir, Zehra Narlı, et al.
Publicado: (2022)

Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?
por: Julius, Ulrich, et al.
Publicado: (2020)

The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Successful Treatment of a 39-Year-Old COVID-19 Patient with Respiratory Failure by Selective C-Reactive Protein Apheresis
por: Torzewski, Jan, et al.
Publicado: (2021)

Fibrinogen/LDL apheresis is a promising rescue therapy for sudden sensorineural hearing loss
por: Canis, Martin, et al.
Publicado: (2012)

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia
por: Connolly, Katherine D., et al.
Publicado: (2014)

Changes in Lipids and Lipoproteins after Selective LDL Apheresis (7-Year Experience)
por: Kolovou, Genovefa, et al.
Publicado: (2012)

Hyperlipoproteinaemia(a) – apheresis and emerging therapies
por: Vogt, Anja
Publicado: (2017)

Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis
por: Fahed, Akl C., et al.
Publicado: (2012)

Use of CMR imaging to assess the effect of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a)
por: Khan, Tina, et al.
Publicado: (2015)

The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina
por: Khan, Tina Z, et al.
Publicado: (2014)

Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
por: Torzewski, Jan, et al.
Publicado: (2022)

“First in Man”: Case Report of Selective C-Reactive Protein Apheresis in a Patient with Acute ST Segment Elevation Myocardial Infarction
por: Ries, Wolfgang, et al.
Publicado: (2018)

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
por: Wang, Anthony, et al.
Publicado: (2016)

Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines
por: Klingel, Reinhard, et al.
Publicado: (2017)

First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection
por: Torzewski, Jan, et al.
Publicado: (2020)

Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia
por: Wen, Jun, et al.
Publicado: (2019)

Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report
por: Russi, Gianpaolo, et al.
Publicado: (2009)

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients
por: Víšek, J., et al.
Publicado: (2021)

Successful completion of pregnancy using apheresis and a balanced dose of coagulation factors in the presence of high thrombophilia and Lp(a) levels in a woman with two previous abortions
por: Schettler, Volker J.J., et al.
Publicado: (2014)

Desialylation of platelet surface glycans enhances platelet adhesion to adsorbent polymers for lipoprotein apheresis
por: Lauková, Lucia, et al.
Publicado: (2020)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Low‐density lipoprotein apheresis is associated with removal of SARS‐CoV‐2 antibodies
por: Bertram, Sebastian, et al.
Publicado: (2022)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Long-term Low-density Lipoprotein Apheresis in a Patient with Refractory Idiopathic Membranous Glomerulonephritis
por: Yabuuchi, Junko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ctvqododesnbn6sj2o46ekv7nc